Literature DB >> 26564251

Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.

Alexis D Leal1, Carrie A Thompson1, Alice H Wang2, Robert A Vierkant2, Thomas M Habermann1, Julie A Ross3, Ruben A Mesa4, Beth A Virnig5, James R Cerhan6.   

Abstract

BACKGROUND: Hormonal and reproductive history has been associated with risk of some hematologic malignancies, but their role in myeloproliferative neoplasms (MPN) is largely unknown.
METHODS: Using a population-based cohort study, we evaluated the association of these factors with risk of MPN overall, and for essential thrombocythemia (ET) and polycythemia vera (PV) specifically. Incident MPN cases from 1993 to 2004 were identified via linkage to Medicare. RR and 95% confidence intervals (CI) were estimated utilizing Cox proportional hazard regression.
RESULTS: After >250,000 person-years of follow-up, 257 cases of MPN were identified (172 ET, 64 PV). Ever use of hormone therapy (HT) was associated with an increased risk of ET (RR = 1.63; 95% CI, 1.19-2.23) but a decreased risk of PV (RR = 0.58; 95% CI, 0.34-0.98). There were no statistically significant associations of oral contraceptives or reproductive factors with MPN risk overall, or by MPN subtype. Bilateral oophorectomy was associated with increased risk of ET (RR = 1.58; 95% CI, 1.11-2.25) and decreased risk of PV (RR = 0.32; 95% CI, 0.12-0.88). There was no association of ovulatory years with ET risk; however, there was increased risk of PV (RR = 1.68 for >36.8 compared with ≤27.6 years; P trend = 0.045). Adjustment for potential confounding factors did not alter these associations.
CONCLUSIONS: HT use and bilateral oophorectomy had opposite associations for ET and PV. Except for ovulatory years and PV risk, reproductive history did not appear to play a role in the etiology of MPN. IMPACT: This study suggests different mechanistic impacts of estrogen, and perhaps distinct etiologies, for the two major MPN subtypes. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26564251      PMCID: PMC4713297          DOI: 10.1158/1055-9965.EPI-15-0613

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  38 in total

1.  Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen.

Authors:  K L Medina; K P Garrett; L F Thompson; M I Rossi; K J Payne; P W Kincade
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County.

Authors:  L Bernstein; R K Ross
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

3.  Medical history risk factors for non-Hodgkin's lymphoma in older women.

Authors:  J R Cerhan; R B Wallace; A R Folsom; J D Potter; T A Sellers; W Zheng; C T Lutz
Journal:  J Natl Cancer Inst       Date:  1997-02-19       Impact factor: 13.506

4.  Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin's lymphoma in women.

Authors:  R A Nelson; A M Levine; L Bernstein
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

5.  Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Authors:  Alexis D Leal; Carrie A Thompson; Alice H Wang; Robert A Vierkant; Thomas M Habermann; Julie A Ross; Ruben A Mesa; Beth A Virnig; James R Cerhan
Journal:  Int J Cancer       Date:  2013-10-15       Impact factor: 7.396

6.  Hormone replacement therapy is not associated with an increased risk of leukemia (United States).

Authors:  Julie A Ross; Penny J Sinner; Cindy K Blair; James R Cerhan; Aaron R Folsom
Journal:  Cancer Causes Control       Date:  2005-06       Impact factor: 2.506

7.  Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study.

Authors:  Katherine H Mildon; Pat Ansell; Eve Roman; Eleanor V Kane
Journal:  Cancer Causes Control       Date:  2010-08-10       Impact factor: 2.506

8.  Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort.

Authors:  Lauren R Teras; Alpa V Patel; Janet S Hildebrand; Susan M Gapstur
Journal:  Leuk Lymphoma       Date:  2012-09-14

9.  Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use.

Authors:  Jennifer S Lee; Paige M Bracci; Elizabeth A Holly
Journal:  Am J Epidemiol       Date:  2008-06-10       Impact factor: 4.897

10.  Exogenous hormone use, reproductive history and risk of adult myeloid leukaemia.

Authors:  J N Poynter; R Fonstad; C K Blair; M Roesler; J R Cerhan; B Hirsch; P Nguyen; J A Ross
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

View more
  2 in total

1.  Association between Cholesterol Level and the Risk of Hematologic Malignancy According to Menopausal Status: A Korean Nationwide Cohort Study.

Authors:  Wonyoung Jung; Keun Hye Jeon; Jihun Kang; Taewoong Choi; Kyungdo Han; Sang-Man Jin; Su-Min Jeong; Dong Wook Shin
Journal:  Biomedicines       Date:  2022-07-06

2.  Combining QSAR Modeling and Text-Mining Techniques to Link Chemical Structures and Carcinogenic Modes of Action.

Authors:  George Papamokos; Ilona Silins
Journal:  Front Pharmacol       Date:  2016-08-30       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.